CancerSCEM: a database of single-cell expression map across various human cancers. Issue Volume 50:Issue D1(2022) (13th October 2021)

• Record Type: Journal Article
• Authors: Zeng, Jingyao; Zhang, Yadong; Shang, Yunfei; Mai, Jialin; Shi, Shuo; Lu, Mingming; Bu, Congfan; Zhang, Zhewen; Zhang, Zaichao; Li, Yang; Du, Zhenglin; Xiao, Jingfa
• Is Part Of: Nucleic acids research. Volume 50:Issue D1(2022)
• Page Start: D1147
• Page End: D1155
• Publication Date: 2021-10-13
• Subjects: Nucleic acids -- Periodicals; Molecular biology -- Periodicals; 572.805
• DOI: 10.1093/nar/gkab905
• Languages: English
• ISSNs: 0305-1048

Abstract

Abstract: With the proliferating studies of human cancers by single-cell RNA sequencing technique (scRNA-seq), cellular heterogeneity, immune landscape and pathogenesis within diverse cancers have been uncovered successively. The exponential explosion of massive cancer scRNA-seq datasets in the past decade are calling for a burning demand to be integrated and processed for essential investigations in tumor microenvironment of various cancer types. To fill this gap, we developed a database of Cancer Single-cell Expression Map (CancerSCEM, https://ngdc.cncb.ac.cn/cancerscem ), particularly focusing on a variety of human cancers. To date, CancerSCE version 1.0 consists of 208 cancer samples across 28 studies and 20 human cancer types. A series of uniformly and multiscale analyses for each sample were performed, including accurate cell type annotation, functional gene expressions, cell interaction network, survival analysis and etc . Plus, we visualized CancerSCEM as a user-friendly web interface for users to browse, search, online analyze and download all the metadata as well as analytical results. More importantly and unprecedentedly, the newly-constructed comprehensive online analyzing platform in CancerSCEM integrates seven analyze functions, where investigators can interactively perform cancer scRNA-seq analyses. In all, CancerSCEM paves an informative and practical way to facilitate human cancer studies, and also provides insights into clinical therapy assessments.